Related Experiment Video

Updated: May 7, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

The EGFR-mTOR pathway and laryngeal cancer angiogenesis

Marco Lionello1, A Lovato, A Staffieri

  • 1Otolaryngology Section, Department of Neurosciences, University of Padova, Padova, Italy, marcolionello@email.it.

European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
|September 26, 2013
PubMed

Insights

Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathways are linked to tumor growth. High microvascular density (MVD) in laryngeal cancer correlates with poor prognosis, suggesting therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Epidermal growth factor receptor (EGFR) is a tyrosine kinase involved in cell transformation and tumor progression.
  • The mammalian target of rapamycin (mTOR) pathway, downstream of EGFR, is activated in various cell functions and implicated in cancer.
  • Both EGFR and mTOR signaling pathways are suggested to regulate angiogenesis, the formation of new blood vessels.

Purpose of the Study:

  • To investigate the expression of EGFR and mTOR in laryngeal squamous cell carcinoma (LSCC).
  • To correlate EGFR and mTOR expression with tumor neo-angiogenesis, assessed by CD105-assessed microvascular density (MVD).
  • To evaluate the prognostic significance of these markers and MVD in LSCC patients.

Main Methods:

  • Retrospective analysis of 76 LSCC patients treated with surgery alone.
  • Immunohistochemical assessment of EGFR, mTOR, and CD105 expression using image analysis.
  • Statistical analysis including univariate and multivariate models to determine correlations and prognostic significance.

Main Results:

  • A strong direct correlation was observed between mTOR and EGFR expression (p = 0.0003).
  • mTOR expression showed a significant direct correlation with CD105-assessed MVD (p = 0.0025).
  • Higher CD105-assessed MVD (>5.28%) was associated with increased recurrence rate (p = 0.026) and shorter disease-free survival (DFS) (p = 0.025).
  • N stage and CD105-assessed MVD were independent prognostic factors for DFS on multivariate analysis.

Conclusions:

  • The EGFR-mTOR pathway is strongly correlated with neo-angiogenesis in LSCC.
  • CD105-assessed MVD is a significant independent prognostic marker for disease-free survival in LSCC.
  • Further investigation of the EGFR-mTOR pathway is warranted to understand its role in LSCC angiogenesis and potential therapeutic targeting.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...